---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-141306"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:33:44.777084+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Agios reports Q1 net loss $94.8M; PYRUKYND launch revenue $0.8M, cash $1.2B

## Summary
- FDA approved PYRUKYND for PK deficiency in Feb 2022; U.S. launch generated $0.8M net revenue in partial quarter.
- Net loss from continuing ops $94.8M vs $90.9M YoY; R&D spend $70.1M, SG&A $31.5M.
- Cash & securities $1.2B (down from $2.4B YoY) due to $802.5M share repurchases in 2021; no need for equity.
- Key 2022 milestones: EMA decision on PYRUKYND by year-end, start pediatric PK studies mid-2022.
- Phase 2a study of AG-946 in MDS to initiate by year-end; AG-946 Phase 1 sickle cell cohort started.

## SEC filing metadata
- accession: 0001193125-22-141306
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312522141306/0001193125-22-141306-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312522141306/d266362d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-141306
- JSON: https://secwatch.observer/filing/0001193125-22-141306.json
- Plain text: https://secwatch.observer/filing/0001193125-22-141306.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.